-
Prevention of Alzheimer’s Dementia in High Risk Populations: A Randomized Controlled Trial of a Combination of Cognitive Remediation and Brain Stimulation
https://braincanada.ca/funded-grants/prevention-of-alzheimer-s-dementia-in-high-risk-populations-a-randomized-controlled-trial-of-a-combination-of-cognitive-remediation-and-brain-stimulationThis project is studying a novel intervention in 250 older persons whose major depression has been successfully treated with an antidepressant medication: a combination of cognitive remediation (CR, consisting of memory and problem solving exercises) plus transcranial Direct Current Stimulation...
-
PRIME-RNA: A platform for in vivo preclinical testing of RNA therapeutics
https://braincanada.ca/funded-grants/prime-rna-a-platform-for-in-vivo-preclinical-testing-of-rna-therapeuticsRNA medicines—short strands of nucleic acids that can turn genes “up” or “down”—have changed how we treat brain diseases. For example, nusinersen for spinal muscular atrophy and tofersen for ALS are given by spinal injection to reach the brain and spinal cord. These breakthroughs show that RNA drugs...
-
Prioritizing Progressive Supranuclear Palsy: a transformative in vivo model of disease pathogenesis with strong translational value for future drug development
https://braincanada.ca/funded-grants/prioritizing-progressive-supranuclear-palsy-a-transformative-in-vivo-model-of-disease-pathogenesis-with-strong-translational-value-for-future-drug-developmentProgressive Supranuclear Palsy (PSP) is a deadly disease of the brain with no cure. Project Overview Progressive Supranuclear Palsy (PSP) is a deadly disease of the brain with no cure. By studying the brains of patients who have died scientists have discovered that PSP brains contain toxic deposits...
-
Probiotic being tested as a potential treatment for ALS in Montreal
https://braincanada.ca/about/news-updates/probiotic-being-tested-as-a-potential-treatment-for-als-in-montrealFrom left to right: Azrieli Future Leader in Canadian Brain Research Chantelle Sephton, ALS Society of Canada Vice President Research Dave Taylor, Brain Canada CEO Viviane Poupon, ALS Canada - Brain Canada Discovery Grant recipients Jasna Kriz and Alex Parker at the ALS Research Forum in Toronto in...
-
Profiling Cortical Excitability in ALS Using Threshold Tracking Transcranial Magnetic Stimulation and Multimodal Biomarkers
https://braincanada.ca/funded-grants/profiling-cortical-excitability-in-als-using-threshold-tracking-transcranial-magnetic-stimulation-and-multimodal-biomarkersRationale: Cortical hyperexcitability has been identified to be a potential driver of ALS pathology leading to excitotoxicity and degeneration of upper motor neurons (UMNs)in the primary motor cortex (M1) and the subsequent degeneration of lower motor neurons (LMNs) in the spinal cord. Project...
-
Program to transform low-survival cancers
https://braincanada.ca/about/news-updates/program-to-transform-low-survival-cancersDr. Gelareh Zadeh, is a Professor at the Department of Surgery, University of Toronto, and Head of Neurosurgery at Toronto Western Hospital. She has been awarded a $4.5 million CCS Breakthrough Team Grant for the project, Developing a comprehensive strategy to implement predictive and targetable...
-
Project MinE
https://braincanada.ca/funded-grants/project-mineis a multi-national initiative with currently participating countries. Project Overview is a multi-national initiative with currently participating countries. The goal is to create a database of whole genome sequences for 15,000 people with ALS and 7,500 control subject. This will provide a global...
-
Project Overview Retina-based optogenetic therapy is a promising approach to restore vision to individuals suffering from retinal degeneration. After photoreceptor degeneration, optogenetics are targeted to remaining retinal neurons that are not intrinsically light sensitive, in order to make them light-responsive. However, due to technical reasons, the nature of light responses in the retina following optogenetic therapy differ from the light responses in healthy retina. It is unknown how altering retinal light responses via optogenetic therapy changes visual responses in visual cortex, and how this affects visual perception. Here, we will examine visual cortex responses and visual perception in mice following retina-based optogenetic therapy. These results will provide a multiscale analysis providing crucial insights into how the nature of retina-based vision restoration affects its efficacy.
https://braincanada.ca/funded-grants/project-overview-retina-based-optogenetic-therapy-is-a-promising-approach-to-restore-vision-to-individuals-suffering-from-retinal-degeneration-after-photoreceptor-degeneration-optogenetics-are-targeted-to-remaining-retinal-neurons-that-are-not-intrinsically-light-sensitive-in-order-to-make-them-light-responsive-however-due-to-technical-reasons-the-nature-of-light-responses-in-the-retina-following-optogenetic-therapy-differ-from-the-light-responses-in-healthy-retina-it-is-unknown-how-altering-retinal-light-responses-via-optogenetic-therapy-changes-visual-responses-in-visual-cortex-and-how-this-affects-visual-perception-here-we-will-examine-visual-cortex-responses-and-visual-perception-in-mice-following-retina-based-optogenetic-therapy-these-results-will-provide-a-multiscale-analysis-providing-crucial-insights-into-how-the-nature-of-retina-based-vision-restoration-affects-its-efficacyAnalyzing low-oxygen areas in deadly brain tumours to counter treatment resistance Shreya Gandhi is studying how oxygen-deprived areas of deadly brain tumours called glioblastoma (GBM) contribute to treatment resistance to improve treatment options and outcomes for people with this type of cancer....
-
Prominent neurobiologist Dr. Samuel Weiss appointed Scientific Director of the CIHR Institute of Neurosciences, Mental Health and AddictionProminent neurobiologist Dr. Samuel Weiss appointed Scientific Director of the CIHR Institute of Neurosciences, Mental Health and Addiction
https://braincanada.ca/about/news-updates/prominent-neurobiologist-dr-samuel-weiss-appointed-scientific-director-of-the-cihr-institute-of-neurosciences-mental-health-and-addictionprominent-neurobiologist-dr-samuel-weiss-appointed-scientific-director-of-the-cihr-institute-of-neurosciences-mental-health-and-addictionOTTAWA, May 4, 2017 /CNW/ – Dr. Roderick McInnes, Acting President of the Canadian Institutes of Health Research (CIHR), along with CIHR’s Governing Council, announced today the appointment of Dr. Samuel Weiss as the new Scientific Director of the CIHR Institute of Neurosciences, Mental Health and...
-
Promising new MS Therapy
https://braincanada.ca/about/news-updates/promising-new-ms-therapyPHOTO: Dr. Fang Liu, Senior Scientist, CAMH A Canadian-led international research team, spearheaded by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) has received nearly $800,000 US ($1,137,868 CAD) in new funding to advance a promising therapy for multiple sclerosis (MS)....
Skip to main content
